Genmab — November 2020

Mcjean

Kommer der ikke flere tilskure i Holbæk?

Mcjean

end i AB

Helge_LarsenPI-redaktør

God morgen.

Plimsoller

God morgen .-)

Plimsoller

Helge_LarsenPI-redaktør

Fredagens aviser med KBHL, DFDS og TDC: https://www.proinvestor.com/investornyt/669558/fredagens-aviser-med-kbhl-dfds-og-tdc

bibob

God morgen.

bibob

OncLive. DuoBody PD-L1 x4 -1BB https://www.onclive.com/view/next-generation-bispecific-antibody-shows-early-clinical-activity-in-advanced-solid-tumors?utm_source=sfmc&utm_medium=email&utm_campaign=11-12-20_OncLiveSS_SITC Conference Coverage eNL_Cabometyx_NON_US_Send&eKey=amFuYm9ydXAxOTc4QGdtYWlsLmNvbQ==

Bulder

Tak bibob. “From the point of view of safety, the [toxicity] profile [of GEN1046] is durable, and it was very much focused on liver safety since previous agonists directed to 4-1BB had problems with this,” noted Melero.

bibob

Jeg hæftede mig også ved de forskellige doser.

bibob

And the MTD was not yet reached.

Solsen

Håber på nye opdaterede data i dag. De må kende resultaterne på yderligere et par måneder af forsøget.

Sukkeralf

Tror jeg ikke vi får - måske lidt løst mellem linierne fra Jan

E_L

i would not expect too much extra data, efficacy data was Sep 29, NSCLC expansian was Oct 12?

E_L

The JAK-STAT pathway regulates CD38 on myeloma cells in the bone marrow microenvironment: therapeutic implications https://ashpublications.org/blood/article-abstract/136/20/2334/461276/The-JAK-STAT-pathway-regulates-CD38-on-myeloma?redirectedFrom=fulltext

E_L

Novel Therapies for Relapsed or Refractory Diffuse Large B-Cell Lymphoma https://www.mdpi.com/1422-0067/21/22/8553/htm

E_L

lol, how to make a headline that will
get people to click on your article, "Janssen combines Darzalex with COVID drug in new multiple myeloma submission" https://pharmaphorum.com/news/janssen-combines-darzalex-with-covid-drug-in-new-multiple-myeloma-submission/

DevOp

Seems data from the NSCLC expansion is unlikely to be presented already, but aren't they compelled to present the data either at a conference or at least one of the medical journals? And if that's the case, I guess ASH would be no good as it's only hematology - but which conference would be a good guess for results then - something in May/June?

Bulder

One of these https://waset.org/oncology-conferences